Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.
Phase of Trial: Phase II/III
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Cladribine (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Leukaemia; Sarcoma; Systemic mastocytosis
- Focus Therapeutic Use
- 26 Aug 2016 Planned primary completion date changed from 1 Mar 2013 to 1 Feb 2017.
- 26 Aug 2016 Planned End Date changed from 1 May 2013 to 1 Jun 2017.
- 20 Jul 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000797-35).